Journal
BMJ CASE REPORTS
Volume 14, Issue 7, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bcr-2021-243975
Keywords
COVID-19; drugs and medicines; respiratory medicine; vaccination; immunisation; infectious diseases
Categories
Ask authors/readers for more resources
This study reports a case of a 43-year-old woman who developed a thrombotic event after receiving the J&J COVID-19 vaccine. It is recommended that patients be informed of the potential for such events to occur in order to obtain informed consent.
As with past illnesses, an approach has been taken to vaccinate the population and halt the spread of COVID-19. On 13 April 2021, the US Food and Drug Administration called for a halt in the administration of the Johnson & Johnson (J&J) COVID-19 vaccine due to reports of thrombosis and thrombocytopenia being associated with vaccination. We present the case of a 43-year-old woman with a history of dyslipidaemia, depression, gastro-oesophageal reflux disease and obesity presenting with dyspnoea, headache and light headedness of 3 days' duration. Ten days prior, she had received the J&J COVID-19 vaccine. She was found to have thrombocytopenia, elevated D-dimers, pulmonary emboli and presented 1 day after discharge with an arterial clot despite being on apixaban. Six other US-based cases of venous thrombotic events are being reviewed at present. Patients should be informed of the possibility of such events to provide informed consent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available